| Followers | 65 |
| Posts | 10174 |
| Boards Moderated | 0 |
| Alias Born | 03/29/2015 |
Saturday, November 19, 2022 8:56:33 PM
You are right in the sense that 80% of Americans with GBM cannot of course come up with the money to pay for DCVax-L under the Specials program.
However, with that said, a high enough percentage of Americans diagnosed with will tap out every resource of friends and family to go to the UK and get treated and that will draw lots of notice and put the FDA under a lot of pressure from Americans of all ideological persuasions. Left-leaning folks will focus on the economic and ethnic inequities with respect to which Americans can and cannot muster the resources to get to the UK. Right leaning folks largely believe that folks who work and have a job with insurance should have an effective treatment under that insurance (only extremists think you have to be able to self-pay all the way to be worthy of life). In short, there will be a clamor from all quarters if an American company is saving lots of British lives but comparatively few American lives.
However, with that said, a high enough percentage of Americans diagnosed with will tap out every resource of friends and family to go to the UK and get treated and that will draw lots of notice and put the FDA under a lot of pressure from Americans of all ideological persuasions. Left-leaning folks will focus on the economic and ethnic inequities with respect to which Americans can and cannot muster the resources to get to the UK. Right leaning folks largely believe that folks who work and have a job with insurance should have an effective treatment under that insurance (only extremists think you have to be able to self-pay all the way to be worthy of life). In short, there will be a clamor from all quarters if an American company is saving lots of British lives but comparatively few American lives.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
